NASDAQ · STIM

Neuronetics, Inc.

Healthcare · Medical - Devices

$2.88▲ 0.88% ($0.02)today

As of 11:27 AM ET

52-week

$0.80$3.44

Market cap

$200.06M

P/E

-6.69

EPS (TTM)

-$0.43

Next earnings

Nov 3, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by 28.15%/yr over the past 4 years.

Selected forecast · Base scenario

9.92%/yr · actual 10-year annualized revenue growth

Year 1 growth: 15.55%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$2.88

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 15.55% · Ending margin 0% · Discount rate 11.16%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 3:27 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 3:28 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 1.23%Revenue (TTM): 39.59%FCF (TTM): 71.59%P/S: 36th pct

What changed

The stock rose 1.23% over the last year. Revenue grew 39.59% over the trailing twelve months. Operating margin moved from -34.45% to -14.74%. Free cash flow grew 71.59% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -14.74%. A decisive move in revenue — currently up 39.59% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad.

CEODaniel L. Reuvers

SectorHealthcare

IndustryMedical - Devices

Employees658

IPO dateJun 28, 2018

https://www.neurostar.com

Market multiples

Forward P/E—

EV/EBITDA-5.43

Enterprise value$147.18M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth9.08%

Gross margin (FY2025)48.48%▼23.8ppvs FY2024

Operating margin (FY2025)-21.08%▲25.1ppvs FY2024

ROE-135.26%▲20.5ppvs FY2025

Analyst consensus

RatingBuy

Target price$5.00▲73.91%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est -$0.08 · Revenue est $40.43M

View

NASDAQ · STIM

Neuronetics, Inc.

Healthcare · Medical - Devices

$2.88▲ 0.88% ($0.02)today

As of 11:27 AM ET

52-week

$0.80$3.44

Market cap

$200.06M

P/E

-6.69

EPS (TTM)

-$0.43

Next earnings

Nov 3, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by 28.15%/yr over the past 4 years.

Selected forecast · Base scenario

9.92%/yr · actual 10-year annualized revenue growth

Year 1 growth: 15.55%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$2.88

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 15.55% · Ending margin 0% · Discount rate 11.16%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 3:27 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 3:28 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 1.23%Revenue (TTM): 39.59%FCF (TTM): 71.59%P/S: 36th pct

What changed

What the market seems to be pricing

What would invalidate this read

Operating margin currently stands at -14.74%. A decisive move in revenue — currently up 39.59% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

CEODaniel L. Reuvers

SectorHealthcare

IndustryMedical - Devices

Employees658

IPO dateJun 28, 2018

https://www.neurostar.com

Market multiples

Forward P/E—

EV/EBITDA-5.43

Enterprise value$147.18M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth9.08%

Gross margin (FY2025)48.48%▼23.8ppvs FY2024

Operating margin (FY2025)-21.08%▲25.1ppvs FY2024

ROE-135.26%▲20.5ppvs FY2025

Analyst consensus

RatingBuy

Target price$5.00▲73.91%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est -$0.08 · Revenue est $40.43M

View